{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06463340",
            "orgStudyIdInfo": {
                "id": "SGR-3515-101"
            },
            "organization": {
                "fullName": "Schr\u00f6dinger, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of SGR-3515 In Participants With Advanced Solid Tumors.",
            "officialTitle": "A First-In-Human, Phase 1, Dose Escalation Study of SGR-3515 In Participants With Advanced Solid Tumors.",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-sgr-in-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-24",
            "studyFirstSubmitQcDate": "2024-06-12",
            "studyFirstPostDateStruct": {
                "date": "2024-06-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Schr\u00f6dinger, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.",
            "detailedDescription": "SGR-3515-101 is a phase 1, fist-in-human, single agent, dose-escalation study designed to evaluate the safety, tolerability, dose limiting toxicities, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of SGR-3515 and to identify the maximum tolerated dose, recommended phase 2 dose and schedule of SGR-3515, in participants with advanced solid tumors hypothesized to be sensitive to Wee1/Myt1 inhibition and any solid tumors with designated molecular perturbation relevant to DNA damage repair pathway, including but not limited to CCNE1 amplification."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ],
            "keywords": [
                "Solid Tumor",
                "Advanced Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 52,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "28-day treatment cycle.",
                    "interventionNames": [
                        "Drug: SGR-3515"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "SGR-3515",
                    "description": "SGR-3515 will be administered orally with an intermittent schedule.",
                    "armGroupLabels": [
                        "Dose Escalation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and severity of adverse events (AEs)",
                    "description": "Incidence and severity of adverse events (AEs) per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0 and changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs); and dose interruptions, dose reductions, dose delays and study drug discontinuation due to AEs.",
                    "timeFrame": "Day 1 to 28 days after the last dose of SGR-3515."
                },
                {
                    "measure": "Incidence of Dose Limiting Toxicities (DLTs)",
                    "description": "Incidence of Dose Limiting Toxicities (DLTs)",
                    "timeFrame": "Day 1 to Day 28 of the first 28-day dosing cycle."
                },
                {
                    "measure": "Incidence of serious adverse events (SAEs)",
                    "description": "Incidence of serious adverse events (SAEs)",
                    "timeFrame": "Day 1 to 28 days after the last dose of SGR-3515"
                },
                {
                    "measure": "Recommended phase 2 dose and schedule",
                    "description": "Recommended phase 2 dose and schedule",
                    "timeFrame": "From day 1 until end of phase I when Maximum Tolerated Dose (MTD) and schedule has been reached and confirmed."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetics: Measures Cmax and Cmin of SGR-3515",
                    "description": "Pharmacokinetics: Cmax and Cmin of SGR-3515",
                    "timeFrame": "Day 1 to Day 28 of first 28-day dosing cycle"
                },
                {
                    "measure": "Pharmacokinetics Measures: t1/2 of SGR-3515",
                    "description": "Pharmacokinetics: t1/2 of SGR-3515",
                    "timeFrame": "Day 1 to Day 28 of first 28-day dosing cycle"
                },
                {
                    "measure": "Pharmacokinetics Measures: tmax of SGR-3515",
                    "description": "Pharmacokinetics: tmax of SGR-3515",
                    "timeFrame": "Day 1 to Day 28 of first 28-day dosing cycle"
                },
                {
                    "measure": "Pharmacokinetics Measures: Area Under the Curve (AUC) of SGR-3515",
                    "description": "Pharmacokinetics: Area Under the Curve (AUC) of SGR-3515",
                    "timeFrame": "Day 1 to Day 28 of first 28-day dosing cycle"
                },
                {
                    "measure": "Efficacy analysis",
                    "description": "Efficacy analysis will be performed for each dose level and include but not limited to objective response rate (ORR), duration of response (DOR), disease control rate (DCR) and duration of disease control (DDC), which will be assessed by investigators",
                    "timeFrame": "Day 1 to end of Phase I study"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of advanced/metastatic solid tumor\n* Measurable disease per RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participant must understand and sign an Informed Consent Form (ICF) prior to any study-related assessments/procedures\n* Adequate bone marrow and organ function\n* Women of child-bearing potential (WOCBP) or males must agree to use highly effective contraception for the duration of study and for 90 days after the last dose of study drug\n\nExclusion Criteria\n\n* Participants with primary Central Nervous System (CNS tumors).\n* Participant has received prior systemic anti-cancer treatments or other investigational agents \u2264 21 days of first dose of study drug, or 5 half-lives, whichever is shorter\n* Participant who has received definitive local control radiation (any dose greater than 50 Gy) \\< 42 days prior to the first dose of study drug.\n* Participant who has received major surgeries \u2264 21 days prior to first dose of study drug\n* Participants who have not recovered to Grade 1 or baseline levels from toxicity or adverse events related to prior treatment for their cancer, excluding Grade 2 alopecia, peripheral neuropathy and ototoxicity.\n* Participant who has another clinically significant invasive malignancy, as determined by the investigator, \u2264 2 years prior to the first dose",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Physician",
                    "role": "CONTACT",
                    "phone": "+15032991150",
                    "email": "sdgr-trials-group@schrodinger.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Margaret Dugan, MD",
                    "affiliation": "CMO/Study Physician",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "NEXT Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mohamad A Salkeni, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        }
    },
    "hasResults": false
}